{"paper_id":"3140bce1-d8b2-4c5d-9229-75bb3f5c267e","body_text":"Page 1/18\nCoexistence of endometriosis in women with\nmature cystic ovarian teratoma may not be rare.\nHeesuk Chae  (  hschae@jbnu.ac.kr )\nResearch\nKeywords: mature cystic teratoma, endometriosis, concomitant diseases\nPosted Date: January 28th, 2020\nDOI: https://doi.org/10.21203/rs.2.21971/v1\nLicense:   This work is licensed under a Creative Commons Attribution 4.0 International License.  \nRead Full License\nVersion of Record: A version of this preprint was published at Journal of Gynecology Obstetrics and\nHuman Reproduction on November 1st, 2020. See the published version at\nhttps://doi.org/10.1016/j.jogoh.2020.101786.\n\nPage 2/18\nAbstract\nBackground\nWe investigated the incidence of endometriosis in women with mature cystic ovarian teratoma and\nanalyzed the clinicopathologic features of this occurrence.\nMethods\nFrom January 2017 through December 2018, we retrospectively studied 71 women who had undergone\ncystectomy for mature cystic ovarian teratoma (n = 55, teratoma group) and coexistence of\nendometriosis and mature cystic ovarian teratoma (n = 16, complex group). Serum anti-Müllerian\nhormone (AMH) levels were measured preoperatively and one month after surgery.\nResults\nSixteen (22.54%) patients had coexistence of endometriosis and mature cystic ovarian teratoma\n(complex group); 55 patients had mature cystic teratoma alone (teratoma group). Early-stage\nendometriosis (stage I) was present in eight patients and advanced-stage endometriosis (stage III or IV)\nwas present in eight. In ve cases (31.25%), the coexistence of endometrioma and mature cystic\nteratoma in the same ovary was observed. The mean operation time was signicantly shorter in the\nteratoma group than in the complex group (61.02 ± 22.74 vs. 86.31 ± 35.35 min, p = 0.007). The complex\ngroup had more dysmenorrhea (43.8% vs. 7.3%, p = 0.002) and a signicantly higher rate of decrease in\nserum anti-Müllerian hormone (AMH) levels (33.06 ± 24.92 vs. 16.31 ± 28.17%, p = 0.048).\nConclusion(s)\nThe prevalence of coexisting endometriosis and mature cystic ovarian teratoma may be underestimated.\nPatients with this rare concurrence may present with worsening dysmenorrhea and damage to ovarian\nreserve after surgery may be greater in patients with coexisting endometriosis than in patients with\nmature cystic teratoma alone.\nBackground\nMature cystic ovarian teratomas (MCTs) or dermoid cysts are the most common ovarian tumor in women\nof reproductive age and account for about 20% of ovarian tumors [1, 2]. MCTs account for approximately\n70% of benign ovarian tumors in women under 30 year of age and 50% of pediatric tumors [3, 4]. They\noccur bilaterally in 10–15% of cases [1]. These tumors are usually asymptomatic and are often\ndiscovered incidentally during routine physical or during radiologic examinations [5, 6] The proportion of\nasymptomatic tumors has been reported to range from 6–64.5% [7, 8, 9, 10]. In addition, MCTs have a\ntendency to grow slowly with an estimated growth rate of 1.67 mm/year [1]. Therefore, recently, expectant\nmanagement of MCTs as an alternative to surgical management has been proposed [1, 3].\n\nPage 3/18\nEndometriosis is a chronic inammatory condition dened by the presence of endometrial tissue with\nglands and stroma outside the uterus [11]. Endometriosis is estimated to affect 10% of women in the\nreproductive age group [12]. The incidence of endometriosis in women with dysmenorrhea is\napproximately 40–60%, whereas it is up to 20–30% in women with subfertility [11, 13].\nAlthough MCTs and endometriosis are common gynecologic disorders occurring in women of\nreproductive age, concomitant MCTs and endometriosis are notably rare and have been reported in few\ncase reports. However, the author has observed some patients with unusual concomitant MCTs and\nendometriosis.\nThe aim of this study was to determine the incidence of endometriosis in patients with a diagnosis of\nMCT who underwent laparoscopy and to clarify further the clinical manifestations of this condition.\nMethods\nPatients\nAll patients operated on for MCTs at the Departments of Obstetrics and Gynecology of the Chonbuk\nNational University Hospital from January 2017 through December 2018 were included in this\nretrospective study. This study was approved by the Institutional Review Board of Chonbuk National\nUniversity Hospital (File number: 2018-05-018-006). The requirement for obtaining informed consent from\nthe patients was not applicable owing to the retrospective nature of the study.\nThe inclusion criteria were as follows: (1) mature cystic ovarian teratoma conrmed by pathology and (2)\nendometriosis diagnosed by a pathology specimen and/or a visual conrmation of endometriosis\nlesions. The exclusion criteria were as follows: (1) patients with a history of previous adnexal surgery, and\n(2) any hormonal treatment, such as oral contraceptives, within six months prior to surgery. All patients\nwere divided into the following groups: patients with MCTs alone (teratoma group) and patients with\nconcomitant MCTs and endometriosis (complex group).\nData regarding the patient’s age, parity, body mass index (BMI), preoperative serum cancer antigen (CA)\n125 and carbohydrate antigen (CA) 19 − 9 level, hemoglobin (Hb) level, serum anti-Müllerian hormone\n(AMH) level, site and size of cyst, stage of endometriosis and pathology reports were retrieved from\noperative reports and medical records. Blood samples were preoperatively measured using\nradioimmunoassay for CA 125 and CA 19 − 9. The cutoff values for CA 125 and CA 19 − 9 was 35 U/mL.\nThe Hb concentration was determined both preoperatively and 24 hours after surgery.\nThe rate of decrease of Hb concentrations was calculated using the following formula:\n[(preoperative Hb concentration – postoperative Day 1 Hb concentration)/(preoperative Hb\nconcentration)] 100(%).\n\nPage 4/18\nThe serum AMH concentrations were measured preoperatively and one month after the surgery. The\nserum AMH level was determined using an enzyme-linked immunoassay kit, AMH Gen II (Beckman\nCoulter, USA).\nThe rate of decrease of serum AMH levels was calculated using the following formula:\n[(preoperative serum AMH level – postoperative month 1 AMH level)/(preoperative serum AMH level)]\n100(%).\nCyst size was determined by preoperative imaging studies including ultrasonography, computed\ntomography (CT), and magnetic resonance imaging (MRI). In the case of bilateral ovarian cysts, the sum\nof their largest diameters was dened as the cyst size. The stage of endometriosis was dened according\nto the revised American Fertility Society classication [14].\nStatistical analysis\nR language ver. 3.3.3 (R Foundation for Statistical Computing, Vienna, Austria) and T&F program ver. 3.0\n(YooJin BioSoft, Korea) were used for all statistical analyses. Data was expressed as mean ± standard\ndeviation for continuous variables. The Mann-Whitney U test or Kruskal-Wallis H test were used to test the\ndifference of continuous clinical measurements between the teratoma group and the complex group\ncomposed of ovarian endometrioma and peritoneal endometriosis. For post hoc analysis, the Bonferroni\nmethod was applied to adjust p value. For categorical variables, data was expressed as sample number\nand percentage, N (%), and p values were computed using the chi-squared test or Fisher’s exact test.\nResults\nA total of 71 patients were included, of whom 55 had teratoma (teratoma group) and 16 had a\ncoexistence of endometriosis and MCTs (complex group). Table 1 presents their demographic and\nclinical characteristics, including serum AMH levels and surgery data.\n\nPage 5/18\nTable 1\nDemographics and clinical characteristics of patients with mature cystic teratoma alone (teratoma\ngroup) and with coexisting mature cystic teratoma and endometriosis (complex group)\nVariable Subgroup N(%) Teratoma Complex p value\nSample No (%)   71(100) 55(77.46) 16 (22.54)  \nAge (years)   71(100) 26.44 ± 6.82 27.38 ± 5.60 0.436\nBMI (kg/m2)   71(100) 23.67 ± 5.81 22.74 ± 4.48 0.685\nParity (n)   71(100)     0.758$\n  0 55(77.5) 41 (74.5) 14 (87.5)  \n  1 6(8.5) 5 (9.1) 1 (6.2)  \n  2 5 (7) 5 (9.1) 0 (0)  \n  3 3(4.2) 2 (3.6) 1 (6.2)  \n  4 1(1.4) 1 (1.8) 0 (0)  \n  5 1(1.4) 1 (1.8) 0 (0)  \nCA125 (U/mL)   71(100) 11.97 ± 7.30 19.03 ± 16.49 0.066\nCA19-9 (U/mL)   71(100) 41.88 ± 92.45 71.51 ± 121.67 0.218\nLargest diameter of cyst (cm)   71(100) 5.85 ± 3.23 7.73 ± 3.19 0.020*\nLaterality of cyst (n)   71(100)     0.368\n  Unilateral 63(88.7) 50 (90.9) 13 (81.2)  \n  Multilateral 8(11.3) 5 (9.1) 3 (18.8)  \nLocularityof cyst (n)   71(100)     0.054\n\nPage 6/18\nVariable Subgroup N(%) Teratoma Complex p value\n  Unilocular 51(71.8) 43 (78.2) 8 (50)  \n  Multilocular 20(28.2) 12 (21.8) 8 (50)  \nPreop Hb level (g/dl)   71(100) 13.21 ± 0.90 13.14 ± 0.78 0.689\nPostop Hb level (g/dl)   71(100) 11.89 ± 0.95 11.58 ± 0.84 0.298\nDecrease of Hb level (g/dl)   71(100) 1.31 ± 0.85 1.56 ± 0.64 0.253\nRate of decrease of serum Hblevels (%)   71(100) 9.82 ± 6.30 11.85 ± 4.69 0.186\nOperation time (min)   70(100) 61.02 ± 22.74 86.31 ± 35.35 0.007**\nStage of EMS   16(100)     NA\n  I 8 (50) 0 (0) 8 (50)  \n  III 7(43.8) 0 (0) 7 (43.8)  \n  IV 1(6.2) 0 (0) 1 (6.2)  \nPreop AMH level (ng/mL)   66(100) 5.38 ± 3.80 4.55 ± 4.08 0.209\nPostop AMH level (ng/mL)   65(100) 3.97 ± 2.52 3.01 ± 2.92 0.077\nDecrease of AMH level(ng/mL)   63(100) 0.99 ± 1.86 1.54 ± 1.82 0.180\nRate of decrease of serumAMH levels (%)   63(100) 16.31 ± 28.17 33.06 ± 24.92 0.048*\nClinical presentation (n)   71(100)      \n  Abdominal pain 12(16.9) 9 (16.4) 3 (18.8) > 0.99#\n  Dysmenorrhea 11(15.5) 4 (7.3) 7 (43.8) 0.002#**\n  Incidental nding 29(40.8) 24 (43.6) 5 (31.2) 0.550#\n\nPage 7/18\nVariable Subgroup N(%) Teratoma Complex p value\n  Irregular vaginalbleeding 19(26.8) 18 (32.7) 1 (6.2) 0.074#\nContinuous variables are expressed as mean ± SD.\nCategorical variables are expressed as sample number and %.\np−values for continuous variables are computed using Mann−Whitney U test (i.e. Wilcoxon rank−sum test).\np−values for categorical variables are computed using Fisher’s exact test, chi−squared test or two sample proportion test.\np−value$: computed using chi−squared test\np−value#: computed using two sample proportion test\nN (%): computed in the total sample or subgroups excluding missing data\nBMI: body mass index\nCA 125: cancer antigen 125\nCA 19−9: carbohydrate antigen 19−9\nHb : hemoglobin\nAMH: anti−Müllerian hormone\nNA: not available\n* p <0.05, ** p <0.01\nNo other parameters concerning age, parity, body mass index, laterality of cyst, and locularity of cyst\ndiffered signicantly between the two groups. Serum CA 125 and CA 19 − 9 values also showed no\nsignicant differences between the two groups. The diameter of the cyst was signicantly larger in the\ncomplex group than in the teratoma group (p = 0.02). The mean operation time in the teratoma group was\nsignicantly shorter with a mean of 61.02 ± 22.74 min vs. 86.31 ± 35.35 min in the complex group (p = \n0.007). However, there was no signicant difference in intraoperative blood loss between the two groups.\nThe rate of decrease in serum AMH levels was signicantly higher in the complex group, with a median of\n33.06 ± 24.92 vs. 16.31 ± 28.17 for the teratoma group (p = 0.048).\nFurther, a comparison of the initial clinical presentation in each group during the visit to doctor is shown\nin Fig. 1. The majority of patients in the teratoma group were asymptomatic (24 cases, 43.6%) and the\nlesions were discovered incidentally during routine ultrasound examination, whereas the most common\n\nPage 8/18\nsymptom in the complex group was dysmenorrhea (7 cases, 43.8%). Dysmenorrhea was more common\nin the complex group than in the teratoma group (43.8% vs. 7.3%, respectively; p = 0.002).\nThe complex group was divided into two subgroups according to lesion type of endometriosis: ovarian\nendometrioma and peritoneal endometriosis. To compare further which pairs of groups were signicantly\ndifferent, post hoc comparison analysis was performed among the three groups: teratoma group, ovarian\nendometrioma subgroup, and peritoneal endometriosis subgroup (Table 2). Signicant differences in the\nlargest diameter of cyst (p = 0.047), operation time (p = 0.02), postoperative serum AMH level (p = 0.045)\nwere found among the three groups. However, the post hoc comparison analysis showed that the\npostoperative serum AMH level alone was signicantly lower in the ovarian endometrioma subgroup than\nin the teratoma group (p = 0.039). The difference in the rate of decrease in the serum AMH levels among\nthe three groups was a borderline level of statistical signicance (p = 0.059), but in the post-hoc\ncomparison analysis, the differences in each subgroups were not statistically signicant although the\ndifference was the largest between the teratoma group and the ovarian endometrioma subgroup (p = \n0.065).\n\nPage 9/18\nTable 2\nMean comparison analysis among teratoma group and the complex group (ovarian endometrioma and\nperitoneal endometriosis)\nVariable Teratoma\n(N = 55,\n77.5%)\nOvarian\nendometrioma\n(N = 5, 7%)\nPeritoneal\nendometriosis\n(N = 11,\n15.5%)\np\nvalue\np\nvalue\n[1]\np\nvalue\n[2]\np\nvalue\n[3]\nAge (years) 26.44 ± 6.82 28.2 ± 5.54 27 ± 5.85 0.659 > 0.99 > 0.99 > 0.99\nBMI (kg/m2) 23.67 ± 5.81 24.01 ± 7.12 22.17 ± 2.94 0.885 > 0.99 > 0.99 > 0.99\nCA125 (U/mL) 11.97 ± 7.3 22.08 ± 13.42 17.65 ± 18.15 0.120 0.193 0.791 > 0.99\nCA19-9(U/mL) 41.88 ± 92.45 112.77 ± 177.63 52.75 ± 91.35 0.262 0.328 > 0.99 0.856\nLargestdiameter ofcyst (cm)\n5.85 ± 3.23 8.98 ± 3.45 7.16 ± 3.06 0.047* 0.112 0.349 > 0.99\nPreop Hb level(g/dl) 13.21 ± 0.9 12.56 ± 0.66 13.41 ± 0.7 0.132 0.210 > 0.99 0.147\nPostop Hblevel (g/dl) 11.89 ± 0.95 11.04 ± 0.76 11.83 ± 0.77 0.147 0.153 > 0.99 0.294\nDecrease ofHb level (g/dl) 1.31 ± 0.85 1.52 ± 0.54 1.58 ± 0.71 0.515 > 0.99 > 0.99 > 0.99\nRate ofdecrease ofserum Hblevels (%)\n9.82 ± 6.3 12.1 ± 4.27 11.73 ± 5.06 0.388 0.821 > 0.99 > 0.99\nOperationtime (min) 61.02 ± 22.74 86.8 ± 22.15 86.09 ± 40.97 0.020* 0.089 0.137 > 0.99\nPreop AMHlevel (ng/mL) 5.38 ± 3.8 2.75 ± 1.8 5.67 ± 4.79 0.167 0.176 > 0.99 0.480\nPostop AMHlevel (ng/mL) 3.97 ± 2.52 1.48 ± 0.94 3.96 ± 3.37 0.045* 0.039* > 0.99 0.245\nDecrease ofAMH level(ng/mL)\n0.99 ± 1.86 1.27 ± 0.93 1.71 ± 2.26 0.391 0.855 0.995 > 0.99\nRate ofdecrease ofserum AMHlevels (%)\n16.31 ± 28.17 43.55 ± 15.29 26.49 ± 28.33 0.059 0.065 > 0.99 0.574\n\nPage 10/18\nVariable Teratoma\n(N = 55,\n77.5%)\nOvarian\nendometrioma\n(N = 5, 7%)\nPeritoneal\nendometriosis\n(N = 11,\n15.5%)\np\nvalue\np\nvalue\n[1]\np\nvalue\n[2]\np\nvalue\n[3]\nVariables are expressed as mean ± SD, and p values are computed using Kruskal−Wallis H test\np−values[1]: computed between the teratoma group and the ovarian endometrioma subgroup using a post−hoc analysis algorithm\nof Bonferroni\np−values[2]: computed between the teratoma group and the peritoneal endometriosis subgroup using a post−hoc analysis\nalgorithm of Bonferroni\np−values[3]: computed between the ovarian endometrioma subgroup and the peritoneal endometriosis subgroup using a post−hoc\nanalysis algorithm of Bonferroni\nBMI: body mass index\nCA 125: cancer antigen 125\nCA 19−9: carbohydrate antigen 19−9\nHb : hemoglobin\nAMH: anti−Müllerian hormone\n* p <0.05\nThe individual clinicopatholgic features of the 16 patients with coexisting MCTs and endometriosis are\nshown in Table 3. In ve patients, the coexistence of MCTs and ovarian endometrioma in a single ovary\nwas observed. In case 5 and case 13, the coexistence of MCTs and ovarian endometrioma with histologic\nadmixture in an ovarian cyst was observed, whereas in the other cases, separate teratomatous and\nendometrial lesions in a single ovary were observed. Further, case 2 had a combination of serous\ncystadenoma and teratoma, whereas, case 6 had teratoma with coincidental ovarian endometrioma and\nserous cystadenoma as a separate pathology.\n\nPage 11/18\nTable 3\nSummary of the clinicopathologic characteristics of the 16 patients with coexistent endometriosis and\nmature cystic ovarian teratoma.\nCase\nno.\nAge\n(yr)\nCA125\n(U/mL)\nCA19-\n9(U/mL)\nPresentation Stage Pathology\n1 26 20.1 47.1 Dysmenorrhea I Teratoma, pelvicendometriosis\n2 25 12.2 321.79 Dysmenorrhea I Teratoma, pelvicendometriosis,serous cystadenoma\n3 26 5.8 26.44 Dysmenorrhea I Teratoma, pelvicendometriosis\n4 36 70.2 71.04 Incidentalndings IV Teratoma, pelvicendometriosis\n5 27 19.2 52.19 Abdominal pain IV Teratoma, ovarianendometrioma\n6 25 24.2 18.17 Abdominal pain III Teratoma, ovarianendometrioma,seous cystadenoma\n7 29 12.9 26.44 Dysmenorrhea I Teratoma, pelvicendometriosis\n8 22 17.4 12.61 Dysmenorrhea I Teratoma, pelvicendometriosis\n9 38 9.2 2.69 Dysmenorrhea II Teratoma, pelvicendometriosis\n10 26 19.9 3.98 Dysmenorrhea I Teratoma, pelvicendometriosis\n11 19 12.3 28.94 Incidentalndings I Teratoma, pelvicendometriosis\n12 25 29.5 429.19 Incidentalndings III Teratoma, ovarianendometrioma\n13 38 1 16.8 Incidentalndings III Teratoma, ovarianendometrioma\n14 26 36.5 47.49 Incidentalndings III Teratoma, ovarianendometrioma\nCA 125: cancer antigen 125\nCA 19−9: carbohydrate antigen 19−9\n\nPage 12/18\nCase\nno.\nAge\n(yr)\nCA125\n(U/mL)\nCA19-\n9(U/mL)\nPresentation Stage Pathology\n15 29 8.3 24.82 Abdominal pain III Teratoma, pelvicendometriosis\n16 21 5.8 14.41 Irregular vaginalbleeding I Teratoma, pelvicendometriosis\nCA 125: cancer antigen 125\nCA 19−9: carbohydrate antigen 19−9\nDiscussion\nThe present study, to the author’s knowledge, is the rst attempt to investigate the incidence of the\ncoexistence of MCTs and endometriosis and to evaluate the differential clinical characteristics of\npatients with this complex condition.\nAlthough MCTs and endometriosis are benign diseases that commonly affect women of reproductive\nage, the coexistence of MCTs and endometriosis, especially in a single ovary, is rare [6, 15, 16]. However,\nin this study, this coexistence was not rare. Although this study included a relatively small number of\npatients, the incidence of coexisting MCTs and endometriosis was 22.54% and its incidence in a single\novary was 7.04%. Recently, Matalliotaki et al. proposed that endometriosis is linked with an increased risk\nof benign gynecological tumor, such as ovarian cyst, adenomyosis and uterine leiomyomas [17]. In that\nstudy, dermoid cysts (1.5%) were observed in women with endometriosis. This data and the present\nstudy’s ndings suggest that coexisting MCTs and endometriosis may be more common than previously\nreported.\nMCTs are often discovered incidentally in asymptomatic women [1, 10]. Patients with MCTs develop\nsymptoms such as discomfort or pain when MCTs are complicated by torsion, rupture, and infection [6].\nHowever, various types of pain are associated with endometriosis: dysmenorrhea, deep dyspareunia, and\npelvic pain unrelated to intercourse or menstruation, such as pain during defecation or urinating [18].\nSonographic examination is the initial method for identifying adnexal cystic structures, but MCTs can be\noccasionally dicult to distinguish from endometriomas, hemorrhagic cyst, and mucinous cystic\nneoplasm based on ultrasonography alone[19], and additional modalities including CT or MRI may be\nneeded. However, the complexity and rarity of coexisting MCTs and endometriosis make it more dicult\nto diagnose. This study demonstrated a high prevalence of coexisting MCTs and endometriosis in those\npresenting with dysmenorrhea. The occurrence of dysmenorrhea was more common among women with\nthis complex condition, whereas most MCTs occurred without clinical symptoms. The diagnosis of\nconcomitant endometriosis in patients with MCTs rests on a high index of suspicion. Thus, gynecologic\nsymptoms such as worsening dysmenorrhea may be a diagnostic clue.\n\nPage 13/18\nFurther, in this study, the operative time was signicantly shorter in patients with MCTs alone than in\npatients with coexisting MCTs and endometriosis. In addition, in one patient with a histologic admixture\nof MCTs and endometriosis in an ovarian cyst, the procedure was converted to laparotomy because of\ndense adhesions and a larger ovarian cyst (exceeding 10 cm in diameter). These observations indicate\nthat concurrent endometriosis with MCTs makes surgery much more dicult.\nThe recommended management of MCTs is generally surgical removal because of a large cyst size, risk\nof torsion, and concern for occult malignancy. Traditionally, MCTs have been removed by elective surgery\nand this procedure accounts for 20–35% of the surgical removal of ovarian tumors [1, 20]. MCTs are the\nmost common germ cell tumors of the ovary in women of reproductive age, and account for\napproximately 70% of benign ovarian neoplasms in women under 30 years of age [21, 22]. The major\nconcern among these younger women is future fertility. Therefore, the appropriate treatment of MCTs in\nchildren and adolescents remains unclear. A retrospective study by Hoo et al. found that the success rate\nof expectant management of MCTs was high and suggested that this approach be considered as a viable\nalternative to surgical management [1]. O’Neill et al. suggested that close follow-up without intervention\nshould be considered to preserve ovarian function and future fertility in children and adolescents with\nMCTs [3]. However, endometriosis found in conjunction with MCTs makes justifying the expectant\napproach even more challenging. Endometriosis is a common disorder in adult women. Goldstein et al.\nreported a 47% prevalence of endometriosis in adolescents undergoing laparoscopy for pelvic pain\n[23.24]. Several studies reported a reduced number of retrieved oocytes for in vitro fertilization and\npremature ovarian failure after surgery for endometriosis [25.26]. The present study’s results showed that\nthe rate of decline of serum AMH levels was signicantly higher in patients with coexisting MCTs and\nendometriosis than in patients with MCTs alone. The study’s small sample size makes generalizing the\nconclusion dicult, but this result suggests that surgical cystectomy for this condition in a single ovary\ncould cause more damage to the ovarian reserve.\nThe malignant transformation of MCTs is an uncommon complication, with an incidence of 0.17–2% [3,\n4]. However, endometriosis is present in about 10–15% of ovarian cancers and is usually associated with\nendometrioid carcinoma or clear cell adenocarcinoma [27]. Moreover, Anteby et al. reported that the\nrecurrence rate of MCTs following cystectomy was 3–4% [28]. Recurrence rates of endometrioma after\nsurgical excision vary considerably, ranging from 6 percent through 30 percent [29.30]. Consequently,\npatients with coexisting MCTs and endometriosis may have an increased risk of malignancy and\nrecurrence.\nFurther, a collision tumor is dened as the coexistence of two adjacent, but histologically distinct tumor\ncomponents [31]. Collision tumors have been reported in various organs including the esophagus,\nstomach, liver, bone, kidney, central nervous system and lung, and so on, but such tumors are relatively\nrare in the ovary [32]. In addition, the most common histologic combination of a collision tumor in the\novary is the coexistence of teratoma and mucinous tumors; therefore a combination of teratoma with\nserous cystadenoma is rare [33].\n\nPage 14/18\nThis study had several limitations. First, not all patients had pathology-conrmed endometriosis. Second,\nthe reverse case–the presence of MCTs in patients with endometriosis– was not considered. In addition,\nthe number of patients analyzed was small.\nConclusions\nThe ndings of this study suggest that the coexistence of MCTs and endometriosis is not as rare as\npreviously thought. This study also showed that among women with MCT, those with coexisting\nendometriosis had marked dysmenorrhea compared to women with MCT alone and that damage to\novarian reserve after cystectomy in women with coexisting endometriosis may be greater than in women\nwith MCT alone. These results can not only help categorizing this complex disease, but can also be used\nto standardize its treatment. Nevertheless, further prospective studies are required to verify whether the\ncoexistence of MCTs and endometriosis is indeed not rare.\nDeclarations\nEthics approval and consent to participate\nThis study was approved by the Institutional Review Board of Chonbuk National University Hospital (IRB\nFile No. 2018-05-018-006 ). Due to the retrospective design of the study an informed consent is not\napplicable.\nConsent for publication\nNot applicable\nAvailability of data and materials\nThe datasets used and/or analysed during the current study are available from the corresponding author\non reasonable request.\nCompeting interests\nThe authors declare that they have no competing interests.\nFunding\nWe did not receive any funding for this study.\nAuthors’ contributions\nHC performed data collection, data analysis, and manuscript writing and editing. The author read and\napproved the nal manuscript.\n\nPage 15/18\nAcknowledgements\nNot applicable\nAbbreviations\nBMI\nbody mass index\nCA 125\ncancer antigen 125\nCA 19 − 9\ncarbohydrate antigen 19 − 9\nHb\nhemoglobin\nAMH\nanti-Müllerian hormone\nReferences\n1. Hoo WL, Yazbek J, Hollland T, Mavrelos D, Tong EN, Jurkovic D. Expectant management of\nultrasonically diagnosed ovarian dermoid cysts: is it possible to predict outcome? Ultrasound Obstet\nGynecol 2010;36:235-40.\n2. Yan L, Li M, Zhang B, Xu X, Xu Z, Han T, et al. Effect of ovarian dermoid cyst excision on ovarian\nreserve and response: Insights from in vitro fertilization. Gynecol Minim Invasive Ther 2016;5:161-5.\n3. O’Neill KE, Cooper AR. The approach to ovarian dermoids in adolescents and young women. J\nPediatr Adolesc Gynecol 2011;24:176-80.\n4. Ayhan A, Bukulmez O, Genc D, Karamursel BS, Ayhan A. Mature cystic teratomas of the ovary: case\nseries from one institution over 34 years. Eur J Obstet Gynecol Repro Biol. 2000;33:153-7.\n5. 5. Stany MP, Hamilton CA. Benign disorders of the ovary. Obstet Gynecol Clin North Am 2008;35:271-\n84.\n. Chae H, Rheu C. Endometriosis coexisting with mature cystic teratoma in the same ovary and ectopic\npregnancy of left fallopian tube: a rare coexistence. Clin Case Rep 2015;3:315-8.\n7. Kim MJ, Kim NY, Lee DY, Yoon BK, Choi D. Clinical characteristics of ovarian teratoma: age-focused\nretrospective analysis of 580 cases. Am J Obstet Gynecol 2011;205:32 e1-4.\n. Peterson WF, Prevost EC, Edmunds FT, Hundley JM, Morris FK. Benign cystic teratomas of the ovary;\na clinic-statistical study of 1,007 cases with a review of the literature. Am J Obstet Gynecol\n1955;70:368-82.\n9. Lakkis WG, Martin MC, Gelfand MM. Benign cystic teratoma of the ovary: a 6-year review. Can J Surg\n1985;28:444-6.\n\nPage 16/18\n10. Comerci JT Jr, Licciardi F, Bergh PA, Gregori C, Breen JL. Mature cystic teratoma: a clinicopathologic\nevaluation of 517 cases and review of the literature. Obstet Gynecol 1994;84:22-8.\n11. Selcuk I, Bozdag G. Recurrence of endometriosis; risk factors, mechanisms and biomarkers; review of\nthe literature. J Turk Ger Gynecol Assoc 2013;14:98-103.\n12. Chandra A, Rho AM, Jeong K, Yu T, Jeon JH, Park SY, et al. Clinical experience of long-term use of\ndienogest after surgery for ovarian endometrioma. Obstet Gynecol Sci 2018;61:111-7.\n13. Farquhar C. Endometriosis. BMJ 2007;334:249-53.\n14. American Society for Reproductive: Revised American Society for Reproductive Medicine\nclassication of endometriosis: 1996. Fertil Steril 1997;67:817-21. .\n15. van der Merwe JL, Siebert I, van Wyk AC. Rare case of perplexing ovarian endometriosis. Fertil Steril\n2010;94:1910.e17-9.\n1. Caruso ML, Pirrelli M. A rare association between ovarian endometriosis and bilateral ovarian\nteratoma. Case report. Minerva Ginecol 1997;49:341-3.\n17. Matalliotaki C, Matalliotakis M, Ieromonachou P, Goulielmos GN, Zervou MI, Laliotis A, et al. Co-\nexistence of benign gynecological tumors with endometriosis in a group of 1,000 women. Oncol Lett\n2018;15:1529-32.\n1. Kinkel K, Frei KA, Balleyguier C, Chapron C. Diagnosis of endometriosis with imaging: a review. Eur\nRadiol 2006;16:285-98.\n19. Patel MD, Feldstein VA, Lipson SD, Chen DC, Filly RA. Cystic teratomas of the ovary: diagnostic value\nof sonography. Am J Roentgenol 1998;171:1061-5.\n20. Nezhat C, Winer W, Nezhat F. Laparoscopic removal of dermoid cysts. Obstet Gynecol 1989;73:278-\n81.\n21. Templeman CL, Fallat ME, Lam AM, Perlman SE, Hertweck SP, O’Connor DM. Managing mature cystic\nteratomas of the ovary. Obstet Gynecol Surv 2000;55:738-45.\n22. Savasi I, Lacy JA, Gerstie JT, Stephens D, Kives S, Allen L. Management of ovarian dermoid cysts in\nthe pediatric and adolescent population. J Pediatr Adolesc Gynecol 2009;22:360-4.\n23. Smorqick N, As-Sanie S, Marsh CA, Smith YR, Quint EH. Advanced stage endometriosis in\nadolescents and young women. J Pediatr Adolesc Gynecol 2014;27:320-3.\n24. Goldstein DP, De Cholnoky C, Emans SJ. Adolescent endometriosis. J Adolesc Health Care 1980;1:37-\n41.\n25. Chen Y, Pei H, Chang Y, Chen M, Wang H, Xie H, et al. The impact of endometrioma and laparoscopic\ncystectomy on ovarian reserve and the exploration of related factors assessed by serum anti-\nMullerian hormone: a prospective cohort study. J Ovarian Res 2014;7:108.\n2. Busacca M, Vignail M. Endometrioma exision and ovarian reserve: a dangerous relation. J Minim\nInvasive Gynecol 2009;16:142-8.\n27. Takahashi K, Kurioka H, Irikoma M, Ozaki T, Kanasaki H, Miyazaki K. Benign or malignant ovarian\nneoplasms and ovarian endometriomas. J Am Assoc Gynecol Laparosc 2001;8:278-84.\n\nPage 17/18\n2. Anteby E, Dubuisson J, Samouth N, Shimonovitz S, Ariel I, Hurwitz A. Germ cell tumors of the ovary\narising after dermoid cyst resections: A long term follow-up study. Obstet Gynecol 1994;83:605-8.\n29. Busacca M, Marana R, Caruana P, Candiani M, Muzil L, Calia C, et al. Recurrence of ovarian\nendometrioma after laparoscopic excision. Am J Obstet Gynecol 1999;180:519-22.\n30. Sesti F, Capozzolo T, Pietropolli A, Marziali M, Bollea MR, Piccione E. Recurrence rate of\nendometrioma after laparoscopic cystectomy: a comparative randomized trial between post-\noperative hormonal suppression treatment or dietary therapy vs. placebo. Eur J Obstet Gynecol\nReprod Biol 2009;147:72-7.\n31. Singh AK, Singh M. Collision tumours of ovary: a very rare case series. J Clin Diagn Res 2014;8:FD14-\n6.\n32. Choudhary S, Adisesha S. Collision tumors of ovary: a rare phenomenon. Int J Case Rep Imag\n2012;3:68-70.\n33. Bige O, Demir A, Koyuncuoglu M, Secil M, Ulukus C, Saygili qu. Collision tumor: serous\ncystadenocarcinoma and dermoid cyst in the same ovary. Arch Gynecol Obstet 2009;279:767-70.\nFigures\n\n\nPage 18/18\nFigure 2\nBar plot representing sample distribution of clinical presentation between the teratoma group and the\ncomplex group. Y axis presented as sample number. Sample percentage (%) of each clinical presentation\npresented inside each bar.","source_license":"CC0","license_restricted":false}